FONAR Stock Gains Post Y/Y Decline in Q1 Earnings and Profit
FONR reports top-line growth for first-quarter fiscal 2026 amid earnings decline and increased SG&A and operating expenses.
FONR Stock Rises Following Q3 Earnings on Higher Net Income
FONAR Corporation's Q3 fiscal 2025 results show higher net income and revenue growth, driven by record MRI scan volumes and strong performance of its HMCA unit.
FONR Stock Declines After Q2 Earnings, Revenue and Net Income Fall
FONAR's second-quarter fiscal 2025 revenues and net income decline. Higher costs and lower scan volumes weigh on results.
FONAR: Assets Remain Too Cheap To Pass Up
Despite recent underperformance, FONAR remains a value play with minimal debt, positive profitability, and attractive valuation multiples, particularly a P/B ratio of 0.61. Q1-Fiscal 2025 earnings showed a decline, but FONAR's book value continues to grow, driven by strategic investments in high-field MRI scanners and new locations. Risks include market punishment for near-term growth rates and low trading volume, but downside risk is limited due to strong financials and shareholder-friendly trends.
FONR Stock Gains Despite Q1 Earnings Dip and Rising Expenses
FONAR's fiscal first-quarter earnings reveals a decline in revenues and income, driven by decreased patient fees and rising costs, while MRI scan volume sees modest growth.
FONR's Stock Down Despite Earnings, Revenues Uptick in Fiscal 2024
Strength in FONAR's HMCA segment's revenues drives its top line in fiscal 2024.
FONAR Corporation: Shares Look Ready To Embark On A Sustained Bullish Run (Technical Analysis)
FONAR Corporation showed encouraging growth trends in revenues and earnings, leading to a 'Buy' rating last year. Recent technical trends suggest a potential long-term change in the stock trend, supported by strong near-term growth rates and a favorable valuation. Forward-looking fundamentals, including the adoption of SwiftMR, indicate potential for continued growth and profitability for FONR shareholders.
Zacks Initiates Coverage of FONAR Corporation With Outperform Recommendation
Discover why Zacks rates FONAR Corporation as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore FONR's strategic expansion, financial health and market positioning for growth in the MRI diagnostic services space.
